New Research Consortium Targets Autoimmune Diseases
A $15 million global project aims to improve care and treatment options for people living with autoimmune conditions.
Updated on Oct. 29, 2026 in Allergies

Live Poll
Does cross-disciplinary collaboration effectively improve long-term outcomes for patients with chronic autoimmune diseases?
A $15 million investment from the Colton Foundation is launching a three-year international research consortium to advance the study of autoimmune diseases. This collaboration between Tel Aviv University, New York University, and Yale University aims to improve treatment development for conditions that impact millions globally.
Why it matters
Autoimmune diseases affect 5% to 8% of the global population, but the complexity of these conditions often necessitates fragmented care. This project seeks to better understand disease triggers and develop therapies that minimize side effects by fostering cross-disciplinary research and integrated patient care.
The initiative represents a formal $15 million funding commitment over three years aimed at addressing the 100 known diseases within the autoimmune group. While the funding structure is set, specific clinical milestones and long-term diagnostic outcomes remain under investigation.
The players
Colton Foundation
A philanthropic organization focused on medical research and supporting the development of advanced autoimmune treatments.
Tel Aviv University
A major research institution that serves as the home for the Colton Center for Autoimmunity.
New York University
A global research university and partner institution in the new international consortium.
Yale University
A leading research university contributing to the collaborative study of immune system disorders.
The details
The consortium integrates diverse expertise from engineering, physics, and mathematics to study how immune systems malfunction. By establishing committees that allow patients to consult with multiple specialists simultaneously, the model addresses comorbidities that often complicate traditional autoimmune treatment. This network approach facilitates shared faculty expertise to uncover the biological triggers behind chronic immune dysfunction.
Timeline
The research initiative is scheduled to run for a three-year period.
Health Landscape
This project marks a shift toward multidisciplinary, cross-institutional cooperation in managing complex immune disorders. It builds upon the work of the Colton Center for Autoimmunity by scaling the effort beyond a single institution to include diverse global academic partners.
For those managing autoimmune conditions, this research effort signals an emerging shift toward integrated care models where multiple specialists coordinate treatment. Patients should ask their primary care providers if their current care team utilizes multidisciplinary committees to manage complex comorbidities.
The takeaway
Advancements in autoimmune care increasingly rely on interdisciplinary collaboration to solve complex health triggers. Consider keeping a detailed log of your symptoms and potential flares to facilitate more effective communication with your specialist team.
Further reading
Learn more about the latest research and management strategies for immune-related conditions in our Allergies section.
Source note: This article includes information reported by The Jerusalem Post.
Live Poll
Does cross-disciplinary collaboration effectively improve long-term outcomes for patients with chronic autoimmune diseases?


